Linagliptin Viatris (Linagliptin)

Linagliptin is a DPP‑4 inhibitor indicated for managing type 2 diabetes mellitus.

• Type 2 diabetes mellitus (monotherapy): improves glycemic control when used alone.
• Type 2 diabetes mellitus (combination therapy): enhances glucose lowering when added to metformin or other oral agents.
• Type 2 diabetes mellitus (adjunct to diet and exercise): helps achieve target HbA1c as part of comprehensive management.

• Linagliptin reversibly binds to the active site of the dipeptidyl peptidase‑4 enzyme, preventing the degradation of incretin hormones such as GLP‑1 and GIP. By maintaining higher incretin levels, it promotes glucose‑dependent insulin secretion, suppresses glucagon release, and slows gastric emptying, resulting in reduced post‑prandial and fasting blood glucose concentrations.

Linagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nasopharyngitis: mild inflammation of the nose and throat.
• Headache: transient cranial pain.
• Upper respiratory tract infection: symptoms of cough, sore throat, or congestion.
• Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain with elevated enzymes.
• Severe allergic reactions: rash, angioedema, or anaphylaxis.
• Bullous pemphigoid: blistering skin disorder.

Before initiating Linagliptin therapy, certain clinical considerations should be reviewed.

• Renal impairment: dose adjustment is not required, but monitor renal function regularly.
• Hepatic impairment: use with caution in patients with moderate liver disease.
• Cardiovascular disease: assess risk as patients with heart failure may need closer observation.
• Elderly patients: start at the recommended dose and monitor for adverse effects.
• Concomitant medications: review for potential interactions, especially with insulin or sulfonylureas.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Linagliptin can affect or be affected by other medicines; interactions are classified by clinical significance.

Major Interactions (Avoid)

• Insulin or sulfonylureas: increased risk of hypoglycemia; dose of the co‑administered agent may need reduction.
• Strong CYP3A4 inhibitors: may raise linagliptin plasma levels, requiring careful monitoring.

Moderate Interactions (Monitor Closely)

• Rifampin: may reduce linagliptin exposure, potentially decreasing efficacy.
• Diuretics: may enhance the glucose‑lowering effect, necessitating glucose monitoring.
• Anticoagulants (e.g., warfarin): monitor INR as occasional alterations have been reported.